Author
@AponiaAnalytics AponiaAnalytics
grade Bx.com/AponiaAnalytics ↗
Numerate biotech catalyst analyst dissecting trial data, dilution, and insider flow
Publishes original, mechanism-aware analysis of biotech/phar
trader score
-1.06
hit rate
36%
mean α
-1.97%
signals 14d
90
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 11 scored bets: 36% hit rate, -1.97% mean alpha, trader score -1.06. Their last-14d mentions, direction-adjusted, have moved -3.7% since posting (mean over 4 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-15 | · | @AponiaAnalytics | · | Reports Elephas' live-biopsy assay predicted immunotherapy benefit in 26 of 28 patients. | · | tweet ↗ |
| 2026-10-15 | · | @AponiaAnalytics | · | Reports FDA Fast Track coverage for invikafusp alfa in TMB-high solid tumors. | · | tweet ↗ |
| 2026-10-15 | KRYS | @AponiaAnalytics | +0.45 | KB113 produced regression in 40 of 47 untreated tumors, with control and durability caveats. | · | tweet ↗ |
| 2026-10-15 | · | @AponiaAnalytics | · | Preclinical study links EXO1 to immune escape and immunotherapy resistance. | · | tweet ↗ |
| 2026-10-15 | · | @AponiaAnalytics | · | Study finds expanded T-cell state was driven more by patient biology than culture medium. | · | tweet ↗ |
| 2026-10-15 | · | @AponiaAnalytics | · | Research reports cancer-associated autoantibodies years before diagnosis in a small cohort. | · | tweet ↗ |
| 2026-10-15 | · | @AponiaAnalytics | · | Preclinical work suggests tofacitinib may reduce checkpoint myocarditis without weakening tumor control. | · | tweet ↗ |
| 2026-10-15 | · | @AponiaAnalytics | · | Mouse study links failed extracellular-DNA clearance to TLR9-mediated tumor-cell senescence. | · | tweet ↗ |
| 2026-10-15 | · | @AponiaAnalytics | · | Study reports roughly fourfold faster modeled lethal-hit delivery by engineered CD8 T cells. | · | tweet ↗ |
| 2026-10-14 | · | @AponiaAnalytics | · | Summarizes research linking radiotherapy, endogenous retroviruses and systemic immune responses. | · | tweet ↗ |
| 2026-10-14 | · | @AponiaAnalytics | · | Summarizes preclinical evidence that tumor-driven macrophage signaling suppresses T-cell activity. | · | tweet ↗ |
| 2026-10-14 | · | @AponiaAnalytics | · | Reports Phase II lung-cancer survival results for earlier checkpoint-inhibitor treatment. | · | tweet ↗ |
| 2026-10-14 | · | @AponiaAnalytics | · | Describes base-edited pancreatic-cancer T cells with improved persistence and antitumor activity. | · | tweet ↗ |
| 2026-10-14 | VSTM | @AponiaAnalytics | +0.45 | Reports encouraging but early response rates for VSTM's VS-7375 in pancreatic cancer. | · | tweet ↗ |
| 2026-10-14 | · | @AponiaAnalytics | · | Summarizes preclinical evidence for reducing immunotherapy myocarditis without losing tumor control. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.